Immunomodulator therapy in inflammatory bowel disease

Digestive Diseases and Sciences

Volumn 39, Issue 9, 1994, Pages 1885-1892

  Choi, Paul M ^a   Targan, Stephan R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Crohn's disease; cytokines; review; T cells; therapy; ulcerative colitis

Indexed keywords

15 DEOXYSPERGUALIN; AZATHIOPRINE; BREQUINAR; CHLOROQUINE; CYCLOSPORIN; CYTOKINE; DISCODERMOLIDE; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; INTERFERON; LEFLUNOMIDE; MERCAPTOPURINE; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; RAPAMYCIN; TACROLIMUS; UNCLASSIFIED DRUG;

CROHN DISEASE; HUMAN; IMMUNOPATHOLOGY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; ULCERATIVE COLITIS;

ANTIBODIES, MONOCLONAL; ANTIMETABOLITES; CYTOKINES; HUMAN; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; INTERFERONS; LYMPHOCYTE ACTIVATION; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0028065380     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/BF02088121     Document Type: Review

References (79)

1. Medical treatment of inflammatory bowel disease
2. Advances in drug therapy for inflammatory bowel disease
3. Immunosuppressive drugs in inflammatory bowel disease. A review of their mechanisms of efficacy and place in therapy
4. Mechanisms of tissue injury in inflammatory bowel disease
5. The role of the mucosal immune system in inflammatory bowel disease
6. Role of mucosal T-cell generated cytokines in epithelial cell injury
7. Activation of peripheral blood and intestinal lamina propria lymphocytes in Crohn's disease. In vivo state of activation and in vitro response to stimulation as defined by the expression of early activation antigens
8. Immune activation genes in inflammatory bowel disease
9. Evidence that activated mucosal T-cells play a role in the pathogenesis of enteropathy in human small intestine
10. Remission of Crohn's disease after human immunodeficiency virus infection
11. Cyclosporine
12. The current status of T-lymphocyte apheresis (TLA) treatment of Crohn's disease
13. Treatment of inflammatory bowel disease with anti-CD4 monoclonal antibody
14. Animal models of inflammatory bowel disease—an overview
15. The effects of azathioprine and 6-MP on immunity
16. Immunosuppressant therapy of inflammatory bowel disease
17. Controlled trial of azathioprine in Crohn's disease
18. National Cooperative Crohn's Disease Study: results of drug treatment
19. Treatment of Crohn's disease with 6-mercaptopurine. A long term randomized double blind study
20. Use of azathioprine or 6-mercaptopurine in the treatment of Crohn's disease
21. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease
22. Long term 6-mercaptopurine treatment in adolescents with Crohn's disease
23. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease
24. The role of azathioprine in the management of ulcerative colitis
25. The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis
26. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis
27. 6-Mercaptopurine in the management of inflammatory bowel disease: Short and long term toxicity
28. Azathioprine and 6-mercaptopurine therapy and colorectal carcinoma in Crohn's disease
29. Preliminary report: Cyclosporin in treatment of severe active ulcerative colitis
30. A placebo controlled, double-blind randomized trial of cyclosporin therapy in active chronic Crohn's disease
31. Cyclosporin in inflammatory bowel disease
32. Cyclosporin for Crohn's disease
33. Recombinant interleukin-1 receptor antagonist blocks the proinflammatory activity of endogenous interleukin-1 in rabbit immune colitis
34. Role of interleukin 1 in inflammatory bowel disease—enhanced production during active disease
35. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease
36. Mayer L, Sachar DB: Efficacy of chloroquine in the treatment of inflammatory bowel disease. Gastroenterology 100:A195, 1991
37. Interferons and interleukin-2 as therapy for malignancy and the acquired immunodeficiency syndrome
38. Interferon beta-1b is effective in relapsing-remitting multiples sclerosis
39. Treatment of Crohn's disease with interferon: A preliminary clinical trial
40. Immunological and clinical effects of interferon-gamma on Crohn's disease
41. Natural killer cell and large granular lymphocyte deficiency in the gut of children with inflammatory bowel disease
42. Intravenous immunoglobulin therapy for active, extensive, and medically refractory idiopathic ulcerative or Crohn's colitis
43. Intestinal transplantation in humans under FK 506
44. The rationale for FK 506 in inflammatory bowel disease
45. Selective immunosuppression
46. Humanized antibodies
47. Experimental allergic encephalomyelitis: successful treatment in vivo with an monoclonal antibody that recognizes T helper cells
48. Lymphokine receptor-directed therapy: A model of immune intervention
49. Cells and cytokines in mucosal immunity and inflammation
50. Lymphokines and the intestinal immune response. Role in inflammatory bowel disease
51. Inflammatory mediators of experimental colitis in rats
52. Increased concentrations of interleukin 1b, interleukin 2, and soluble interleukin-2 receptors in endoscopical mucosal biopsy specimens with active inflammatory bowel disease
53. Interleukin-1-induced pathophysiology: Induction of cytokines, development of histopathologic changes and immunopharmacologic intervention
54. Evaluation of an interleukin-1 receptor antagonist in the rat acetic acid-induced colitis model
55. The IL-2/Il-2 receptor system: a current overview
56. Interleukin-2 activity of colonic lamina propria mononuclear cells in a rat model of experimental colitis
57. Plasma interleukin-2 and a soluble/shed interleukin-2 receptor in serum of patients with Crohn's disease
58. Symptomatic exacerbation of Crohn's disease after treatment with high-dose interleukin-2
59. Anti-interleukin-2 receptor antibody suppresses murine diabetic insulinitis and lupus nephritis
60. The role of interleukin 2 in autoimmunity
61. New clinical trials with interleukin-2: rationale for regional administration
62. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation
63. Serum concentration of tumour necrosis factor α in childhood chronic inflammatory bowel disease
64. Acute in vivo effects of human recombinant tumor necrosis factor
65. Tumor necrosis factor antibody treatment in Crohn's disease
66. Expression of leukocyte adhesion molecules in inflammatory bowel disease
67. Prevention and reversal of experimental colitis by a monoclonal antibody which inhibits leukocyte adherence